Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.
Pavlakis K, Bobos M, Batistatou A, Kotoula V, Eleftheraki AG, Stofas A, Timotheadou E, Pentheroudakis G, Psyrri A, Koutras A, Pectasides D, Papakostas P, Razis E, Christodoulou C, Kalogeras KT, Fountzilas G. Pavlakis K, et al. Among authors: koutras a. Pathol Oncol Res. 2015 Apr;21(2):273-82. doi: 10.1007/s12253-014-9818-2. Epub 2014 Aug 8. Pathol Oncol Res. 2015. PMID: 25098276 Free article.
Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG).
Christodoulou C, Kalofonos HP, Briasoulis E, Bafaloukos D, Makatsoris T, Koutras A, Skarlos DV, Samantas E. Christodoulou C, et al. Among authors: koutras a. Cancer Chemother Pharmacol. 2006 Jan;57(2):207-12. doi: 10.1007/s00280-005-0034-3. Epub 2005 Jul 19. Cancer Chemother Pharmacol. 2006. PMID: 16028103 Clinical Trial.
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
Fountzilas G, Bobos M, Kalogera-Fountzila A, Xiros N, Murray S, Linardou H, Karayannopoulou G, Koutras AK, Bafaloukos D, Samantas E, Christodoulou C, Economopoulos T, Kalogeras KT, Kosmidis P. Fountzilas G, et al. Among authors: koutras ak. Cancer Invest. 2008 Oct;26(8):784-93. doi: 10.1080/07357900801918611. Cancer Invest. 2008. PMID: 18798073 Clinical Trial.
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group.
Koutras AK, Fountzilas G, Dafni U, Dimopoulos MA, Pectasides D, Klouvas G, Papakostas P, Kosmidis P, Samantas E, Gogas H, Briasoulis E, Vourli G, Petsas T, Xiros N, Kalofonos HP; Hellenic Cooperative Oncology Group. Koutras AK, et al. Anticancer Res. 2008 Sep-Oct;28(5B):2913-20. Anticancer Res. 2008. PMID: 19031934 Free article. Clinical Trial.
The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP. Koutras AK, et al. Crit Rev Oncol Hematol. 2010 May;74(2):73-8. doi: 10.1016/j.critrevonc.2009.04.011. Epub 2009 May 30. Crit Rev Oncol Hematol. 2010. PMID: 19481955 Review.
Bevacizumab in the treatment of breast cancer.
Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP. Koutras AK, et al. Cancer Treat Rev. 2010 Feb;36(1):75-82. doi: 10.1016/j.ctrv.2009.10.007. Epub 2009 Nov 22. Cancer Treat Rev. 2010. PMID: 19932567 Review.
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.
Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: koutras ak. Breast Cancer Res Treat. 2011 May;127(1):179-93. doi: 10.1007/s10549-011-1427-0. Epub 2011 Mar 9. Breast Cancer Res Treat. 2011. PMID: 21390496 Free article.
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, Papandreou CN, Papakostas P, Bafaloukos D, Repana D, Razis E, Pectasides D, Dimopoulos AM. Fountzilas G, et al. Among authors: koutras a. Anticancer Res. 2011 Sep;31(9):3007-18. Anticancer Res. 2011. PMID: 21868552
Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.
Pectasides D, Papaxoinis G, Kotoula V, Fountzilas H, Korantzis I, Koutras A, Dimopoulos AM, Papakostas P, Aravantinos G, Varthalitis I, Kosmidis P, Skarlos D, Bournakis E, Bafaloukos D, Kalofonos HP, Kalogeras KT, Fountzilas G. Pectasides D, et al. Among authors: koutras a. Oncol Rep. 2012 Jan;27(1):216-24. doi: 10.3892/or.2011.1504. Epub 2011 Oct 13. Oncol Rep. 2012. PMID: 22025320 Clinical Trial.
216 results